Microvast Holdings announces departure of chief financial officer
On June 3, 2025, Brad Hively, a director at Oncology Institute, Inc. (NASDAQ:TOI), sold a substantial portion of his holdings in the company. The transaction comes as TOI’s stock has seen remarkable growth, with a 1,338% return over the past six months. Hively sold a total of 1,976,137 shares of common stock at a price of $2.8703 per share, resulting in a total transaction value of approximately $5.67 million. According to InvestingPro analysis, TOI is currently undervalued despite its recent performance.
In addition to the sales, Hively also acquired shares through multiple exercises of stock options. These acquisitions totaled 1,867,605 shares of common stock, with prices ranging from $0.481 to $1.87 per share, amounting to approximately $1.68 million in value. InvestingPro data shows the company maintains a GOOD financial health score, with particularly strong price momentum metrics.
Following these transactions, Hively’s direct ownership stands at 603,501 shares. For deeper insights into insider trading patterns and comprehensive analysis, subscribers can access the full TOI research report on InvestingPro, which covers over 1,400 US stocks.
In other recent news, The Oncology Institute reported its financial results for the first quarter of 2025, showing a 10.3% increase in revenue year-over-year, reaching $104.4 million. Despite the revenue growth, the company reported an earnings per share (EPS) of -$0.21, missing market expectations. The Oncology Institute also improved its adjusted EBITDA and free cash flow, indicating better operational efficiency. The company reaffirmed its full-year 2025 guidance, projecting revenue between $460 million and $480 million. Additionally, The Oncology Institute announced its inclusion in the Russell 2000 and 3000 indexes, marking a significant milestone in its growth journey. Analyst firm BTIG initiated coverage on The Oncology Institute with a Buy rating and a price target of $7.00, highlighting the company’s high-margin capitated contracts and potential growth in fee-for-service revenue. These developments reflect The Oncology Institute’s strategic focus on improving financial performance while managing complex care for oncology patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.